Medtronic: First Procedures Performed in Trial of Technology for Atrial Fibrillation
05 March 2021 - 1:57AM
Dow Jones News
By Michael Dabaie
Medtronic PLC said the first procedures were performed in the
investigational device exemption pivotal trial of the PulseSelect
Pulsed Field Ablation System.
PulseSelect uses pulsed electric fields to treat atrial
fibrillation.
The first procedure in the PULSED AF pivotal trial was performed
this week at Southcoast Health in Fall River, Mass., with the
second procedure also at Southcoast Health. The PULSED AF Trial
aims to establish the safety and efficacy of the PulseSelect
System.
Atrial fibrillation is one of the most common and undertreated
heart rhythm disorders, affecting more than 37 million people
worldwide. The disease involves an irregular quivering or rapid
heart rhythm in the upper chambers of the heart.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 04, 2021 09:42 ET (14:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2024 to May 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From May 2023 to May 2024